XML 39 R27.htm IDEA: XBRL DOCUMENT
v3.20.2

License and Collaboration Agreements - Additional Information (Details) - USD ($) |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | ---
Jan. 31, 2020 | Jan. 10, 2020 | Dec. 05, 2019 | Nov. 30, 2019 | Nov. 20, 2019 | Jan. 31, 2020 | Dec. 31, 2019 | Apr. 30, 2018 | Mar. 31, 2018 | Feb. 28, 2018 | Mar. 31, 2017 | Sep. 30, 2020 | Jun. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License fee |  |  |  |  |  |  |  |  |  |  |  | $ 25,000 |  | $ 133,333 | $ 58,333 | $ 408,333
Microchips Biotech, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Current portion of contingent consideration |  |  |  | $ 1,000,000.0 | $ 1,000,000.0 |  |  |  |  |  |  |  |  |  |  |
Microchips Biotech, Inc. | Common stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock issued to microchips capital stock holders (in shares) |  |  |  | 2,999,990 |  |  |  |  |  |  |  |  |  |  |  |
Upon Achievement of Specified Development and Regulatory Milestones | Microchips Biotech, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  | 46,500,000 |  |  |  |  |  |  |  |  |  |  |
Current portion of contingent consideration |  |  |  |  | $ 55,000,000.0 |  |  |  |  |  |  |  |  |  |  |
ADVA Tec Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of royalty rate |  |  |  |  |  |  |  |  |  |  | 10.00% |  |  |  |  |
ADVA Tec Agreement | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of royalty rate |  |  |  |  |  |  |  |  |  |  | 1.00% |  |  |  |  |
ADVA Tec Agreement | Upon Achievement of Specified Development and Regulatory Milestones | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  |  |  |  |  | $ 14,600,000 |  |  |  |  |
Bayer Healthcare License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront license fee paid |  |  |  |  |  | $ 1,000,000.0 |  |  |  |  |  |  |  |  |  |
Revenue from grant for notice of award |  |  |  |  |  | $ 20,000,000.0 |  |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount |  | $ 310,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licensing Agreements | ADVA Tec Agreement | Upon Reaching Certain Worldwide Net Sales Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  |  |  |  |  | $ 20,000,000.0 |  |  |  |  |
Licensing Agreements | MilanaPharm |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License fee |  |  |  |  |  |  | $ 25,000 |  |  |  |  |  |  |  |  |
License fee to be paid upon contingency | $ 110,000 |  | $ 100,000 |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement termination periodic discontinued sale of product |  |  | 60 days |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement termination period due to performance failure |  |  | 120 days |  |  |  |  |  |  |  |  |  |  |  |  |
Certain clinical and regulatory development milestone payments |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |
Licensing Agreements | Upon Achieving Certain Development Milestones | MilanaPharm | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount |  |  |  |  |  |  | $ 300,000 |  |  |  |  |  |  |  |  |
Licensing Agreements | Upon Achieving Certain Commercial Milestones | MilanaPharm |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount |  |  |  |  |  |  |  |  |  |  |  |  | $ 50,000 |  |  |
Licensing Agreements | Upon Achieving Certain Commercial Milestones | MilanaPharm | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,750,000 |  |  |
Assignment Agreement | Hammock Pharmaceuticals, Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License fee |  |  | $ 250,000 |  |  |  |  |  |  |  |  |  |  |  |  |
License fee to be paid upon contingency | $ 137,500 |  | $ 125,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Assignment Agreement | Upon Achieving Certain Clinical and Regulatory Development Milestones | Hammock Pharmaceuticals, Inc | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,100,000 |
Milestone Payments |  |  |  |  |  |  |  |  |  |  |  | $ 100,000 |  |  |  |
License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of rights to inventions by employees under license agreement |  |  |  |  |  |  |  |  |  | 50.00% |  |  |  |  |  |
License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount |  |  |  |  |  |  |  |  |  | $ 18,000,000.0 |  |  |  |  |  |
License and Collaboration Agreement | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount |  |  |  |  |  |  |  |  |  | 500,000 |  |  |  |  |  |
License and Collaboration Agreement | Upon Achieving Certain Commercial Milestones | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount |  |  |  |  |  |  |  |  |  | 100,000,000.0 |  |  |  |  |  |
License and Collaboration Agreement | Upon Achieving Certain Commercial Milestones | Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, contingent amount |  |  |  |  |  |  |  |  |  | $ 10,000,000.0 |  |  |  |  |  |
Juniper Pharmaceuticals, Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront license fee paid |  |  |  |  |  |  |  | $ 250,000 |  |  |  |  |  |  |  |
Potential annual license maintenance fee, payments in year one |  |  |  |  |  |  |  | 50,000 |  |  |  |  |  |  |  |
Potential annual license maintenance fee payments, thereafter |  |  |  |  |  |  |  | 100,000 |  |  |  |  |  |  |  |
Juniper Pharmaceuticals, Inc | Clinical and Regulatory Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum potential milestone payments |  |  |  |  |  |  |  | 13,500,000 |  |  |  |  |  |  |  |
Juniper Pharmaceuticals, Inc | Sales Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum potential milestone payments |  |  |  |  |  |  |  | $ 30,300,000 |  |  |  |  |  |  |  |
Development and Option Agreement | Adare |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  |  |  | $ 300,000 |  |  |  |  |  |  |
Commencement period for stage two upon achievement of stage one |  |  |  |  |  |  |  |  | 90 days |  |  |  |  |  |  |
Development and Option Agreement | Upon Signing of Development and Option Agreement | Adare |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  |  |  | $ 150,000 |  |  |  |  |  |  |
Development and Option Agreement | Upon Completion of Fifty Percent Development Not Later Than Six Months | Adare |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  |  |  | $ 75,000 |  |  |  |  |  |  |
Percentage of rights to inventions by employees under license agreement |  |  |  |  |  |  |  |  | 50.00% |  |  |  |  |  |  |
Development and Option Agreement | Upon Delivery of Six Month Batch Development Not Later Than Eleven Months | Adare |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  |  |  | $ 75,000 |  |  |  |  |  |  |

X
- Definition Asset Acquisition, Contingent Consideration, Current + References No definition available. + Details
Name: | dare_AssetAcquisitionContingentConsiderationCurrent
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Commencement Period For Stage Two Upon Achievement Of Stage One + References No definition available. + Details
Name: | dare_CommencementPeriodForStageTwoUponAchievementOfStageOne
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement Notice Period Of Termination + References No definition available. + Details
Name: | dare_LicenseAgreementNoticePeriodOfTermination
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License agreement, termination period due to performance failure. + References No definition available. + Details
Name: | dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement Termination Periodic Discontinued Sale Of Product + References No definition available. + Details
Name: | dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct
Namespace Prefix: | dare_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Fee + References No definition available. + Details
Name: | dare_LicenseFee
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License Fee, To Be Paid Upon Contingency + References No definition available. + Details
Name: | dare_LicenseFeeToBePaidUponContingency
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum Potential Milestone Payments + References No definition available. + Details
Name: | dare_MaximumPotentialMilestonePayments
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone Payments + References No definition available. + Details
Name: | dare_MilestonePayments
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payments, contingent amount. + References No definition available. + Details
Name: | dare_MilestonePaymentsContingentAmount
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of rights to inventions by employees under license agreement. + References No definition available. + Details
Name: | dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement
Namespace Prefix: | dare_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of royalty rate. + References No definition available. + Details
Name: | dare_PercentageOfRoyaltyRate
Namespace Prefix: | dare_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential Annual License Maintenance Fee, Payments In Year One + References No definition available. + Details
Name: | dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Potential Annual License Maintenance Fee Payments, Thereafter + References No definition available. + Details
Name: | dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Research and development milestone payment. + References No definition available. + Details
Name: | dare_ResearchAndDevelopmentMilestonePayment
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront License Fee Paid + References No definition available. + Details
Name: | dare_UpfrontLicenseFeePaid
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dare_BayerHealthcareLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponReachingCertainWorldwideNetSalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_MilanaPharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainDevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainCommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dare_AssignmentAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_HammockPharmaceuticalsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ClinicalAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dare_DevelopmentAndOptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_AdarePharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=dare_UponSigningOfDevelopmentAndOptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=dare_UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |